ABOUT EIRGEN PHARMA
Eirgen Pharma is a specialist OSD CDMO in Waterford, Ireland, providing end‑to‑end development, manufacturing, and supply solutions for high‑potency and conventional medicines. We help innovators progress challenging programmes with confidence—from concept to commercial scale.
Founded in 2005, Eirgen Pharma has grown into a global leader in developing and manufacturing high-potency medicines. We specialize in softgel capsules, film-coated tablets, and powder or liquid-filled hard-shell capsules.
We focus on complex pharmaceuticals, especially oncology therapies, and are proud to be a trusted CDMO and CMO partner to many of the world's top pharmaceutical companies.
Since becoming part of the OPKO Health family in 2015, we've expanded both our R&D capabilities and GMP-compliant manufacturing facilities. Our newest facility - launching in Q3 of 2025 - will allow for an additional 1-billion-unit capacity by 2027, strengthening our ability to deliver innovation, meet global regulatory standards (FDA, EMA, HPRA, PMDA), and support customers worldwide with a robust supply chain.
Under the leadership of Chief Executive Officer, Damien Burke, Eirgen Pharma now supplies life-changing medicines to patients in over 60 countries, including the United States, Europe, Japan, Canada, the Middle East, Australia, and Africa.
Irish By Origin. Global By Impact. Achieving Excellence Together.
.jpg)
20 Years Achieving Excellence Together
Our
Path
Grow our pipeline and presence, powered by investment in our people, technology, and capability.
Our Customer Experience in Numbers
Our Future
Become a world leader in complex medicines
